Publication: Serum transforming growth factor-β1 and epidermal growth factor in biliary atresia
Submitted Date
Received Date
Accepted Date
Issued Date
2008-12-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
09397248
eISSN
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-58149288001
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
European Journal of Pediatric Surgery. Vol.18, No.6 (2008), 415-418
Citation
Paisarn Vejchapipat, A. Theamboonlers, S. Poomsawat, S. Chittmittrapap, Y. Poovorawan (2008). Serum transforming growth factor-β1 and epidermal growth factor in biliary atresia. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/19445.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Serum transforming growth factor-β1 and epidermal growth factor in biliary atresia
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Other Contributor(s)
Series
Has Part
Abstract
Background and Aim: Biliary atresia (BA) is a serious liver disease in children. Since transforming growth factor-β1 (TGF-β1) and epidermal growth factor (EGF) are involved in the hepatic reparative process, our objective was to investigate whether serum TGF-β1 and serum EGF levels were associated with therapeutic outcomes in BA. Methods: Serum levels of TGF-β1 and EGF were determined with the ELISA method in 67 postoperative BA patients with a median age of 7 years and in 10 age-comparable healthy children. The BA patients were then divided into two groups depending on their therapeutic outcome: good outcome (jaundice-free) and poor outcome (persistent jaundice). Clinical data, serum TGF-β1 and serum EGF levels were compared between the two groups of BA patients. Correlation analysis of serum TGF-β1 with serum EGF was carried out. Data are expressed as mean ±SD. Results: Serum TGF-β1 levels of BA patients were higher than those of controls (86.6 ± 15.7 vs. 75.7 ± 8.8 ng/ml, p = 0.0362). However, there was no difference in serum EGF between BA patients and controls (133.1 ± 66.6 vs. 125.4 ± 88.9 pg/ ml, p=0.744). Further subgroup analysis showed that patients with good outcomes (n=40) had higher serum TGF-β1 and serum EGF levels than patients with poor outcomes (TGF-β1: 91.2 ± 16.5 vs. 79.6 ± 11.7 ng/ml, p = 0.002; EGF: 148.5 ± 65.0 vs. 110.3 ± 63.4 pg/ml, p = 0.02). In addition, serum TGF-β1 was positively correlated with serum EGF (Pearson's r = 0.3418, p = 0.0046). Conclusion: Elevated serum TGF-β1 and serum EGF levels were associated with a good outcome in BA patients. There was a positive correlation between serum TGF-β1 and serum EGF. This suggests that the resultant TGF-β1 and EGF pathways may be involved in the pathophysiological process in postoperative BA. © Georg Thieme Verlag KG Stuttgart.